Table of Contents
1 Report Prologue
2 Market Introduction
2.1 Introduction
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
4 Market Dynamics
4.1 Drivers
4.2 Restraints
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
6. Global Vaccines Adjuvants Market, by Type
6.1 Pathogen Components
6.2 Particulate Adjuvants
6.3 Others
7. Global Vaccines Adjuvants Market, by Route of Administration
7.1 Oral
7.2 Intramuscular
7.3 Subcutaneous
7.4 Intradermal
8. Global Vaccines Adjuvants market, by End User
8.1 Pediatric
8.2 Adults
9. Global Vaccines Adjuvants Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 UK
9.3.1.3 France
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of Middle East & Africa
10 Competitive Landscape
10.1 Introduction
10.2 Market share Analysis
10.3 Key Development & Strategies
11 Company Profile
11.1 VaxLiant LLC.
11.1.1 Overview
11.1.2 Product/Business Segment Overview
11.1.3 Financial Updates
11.1.4 Key Developments
11.2 Vaxine Pty Ltd
11.2.1 Overview
11.2.2 Product/Business Segment Overview
11.2.3 Financial Updates
11.2.4 Key Developments
11.3 Aphios Corporation
11.3.1 Overview
11.3.2 Product/Business Segment Overview
11.3.3 Financial Updates
11.3.4 Key Development
11.4 Viscogel AB
11.4.1 Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Updates
11.4.4 Key Development
11.5 Sergeant Adjuvants
11.5.1 Overview
11.5.2 Product/Business Segment Overview
11.5.3 Financial Updates
11.5.4 Key Developments
11.6 Sigma-Aldrich Co. LLC.
11.6.1 Overview
11.6.2 Product/Business Segment Overview
11.6.3 Financial Updates
11.6.4 Key Developments
11.7 CureVac AG
11.7.1 Overview
11.7.2 Product/Business Segment Overview
11.7.3 Financial Updates
11.7.4 Key Developments
11.8 CSL Limited
11.8.1 Overview
11.8.2 Product/Business Segment Overview
11.8.3 Financial Updates
11.8.4 Key Developments
11.9 OZ Biosciences
11.9.1 Overview
11.9.2 Product/Business Segment Overview
11.9.3 Financial Updates
11.9.4 Key Developments
11.9 Others
12 Conclusion
12.1 Key Findings
12.1.1 From CEO’s Viewpoint
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Vaccine Industry
13 Appendix